ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 3, 1996, Pages 203-209

  Holm, Bente ^a   Jensen, Peter Buhl ^a   Sehested, Maxwell ^b  

^a Rigshospitalet   (Denmark)

^b AMAGER HOSPITAL   (Denmark)

Author keywords

Brain tumor model; Etoposide effect regulation in vivo; High dose chemotherapy; ICRF 187, ADR 529; Topoisomerase II poisons; Topoisomerase II rescue

Indexed keywords

AMSACRINE; ETOPOSIDE; GYRASE INHIBITOR; PACLITAXEL; PROTECTIVE AGENT; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER GRAFT; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG ANTAGONISM; EHRLICH ASCITES TUMOR; FEMALE; HYDROPHILICITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LETHALITY; LEUKEMIA L 1210; LEUKOCYTE COUNT; LIFESPAN; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARCINOMA, EHRLICH TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; FEMALE; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; LEUKEMIA L1210; MALE; MICE; MICE, INBRED DBA; PACLITAXEL; RAZOXANE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029891617     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050472     Document Type: Article

References (31)

1. Berger NA (1993) Alkylating agents. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 400
2. Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH (1991) Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 9 : 1627
3. Chu E, Takimoto CH (1993) Antimetabolites. Antifolates. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 358
4. Cornfield J, Mantel N (1950) Some new aspects of the application of maximum likelihood to the calculation of the dosage response curve. J Am Stat Assoc 45 : 181
5. Danø K (1971) Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. Cancer Chemother Rep 55 : 133
6. Donelli MG, Zucchetti M, D'Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30 : 251
7. Finlay GF, Wilson WR, Baguley BC (1989) Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur J Cancer Clin Oncol 25 : 1695
8. Giuliani F, Casazza AM, Di Marco A, Savi G (1981) Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Cancer Treat Rep 65 : 267
9. Herman EH, Mhatre RM, Chadwick DP (1974) Modification of some of the toxic effects of daunomycin (NSC-82, 151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129, 943). Pharmacol Appl Toxicol 27 : 517
10. Herman E, Ardalan B, Bier C, Waravdekar V, Krop S (1979) Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep 63 : 89
11. Herman EH, Witiak DT, Hellmann K, Waravdekar VS (1982) Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 19 : 249
12. Herman EH, El-Hage AN, Ferrans VJ, Witiak DT (1983) Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 40 : 217
13. Holm B, Jensen PB, Sehested M, Hansen HH (1994) In vivo inhibition of etoposide (VP-16) mediated apoptosis, toxicity, and antitumour effect by the topoisomerase II uncoupling anthracycline aclarubicin. Cancer Chemother Pharmacol 34 : 503
14. Jensen PB, Roed H, Skovsgaard T, Friche E, Vindeløv LL, Hansen HH, Spang-Thomsen M (1990) Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother Pharmacol 27 : 194
15. Jensen PB, Sørensen BS, Demant EJF, Sehested M, Jensen PS, Vindeløv L, Hansen HH (1991) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 51 : 3311
16. Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O, Hansen HH (1991) Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51 : 5093
17. Jensen PB, Sørensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E, Hansen HH (1993) Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45 : 2025
18. Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJF, Hansen HH (1994) Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54 : 2959
19. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58 : 351
20. Pommier Y, Kohn K (1989) Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Glazer RI (ed) Development in cancer chemotherapy. CRC, Boca Raton, p 175
21. Pommier Y, Covey J, Kerrigan D, Mattes W, Markovits J, Kohn KW (1987) Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol 36 : 3477
22. Roca J, Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77 : 609
23. Roca J, Ishida R, Berger JM, Andoh T, Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91 : 1781
24. Rowe T, Kupfer G, Ross W (1985) Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA-cleavage. Biochem Pharmacol 34 : 2483
25. Sehested M, Jensen PB, Sørensen BS, Holm B, Friche E, Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1, 2-bis(3, 5-dioxopiperazinyl-1-yl) propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46 : 389
26. Skipper HE, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 : 1
27. Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51 : 4903
28. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226 : 466
29. Von Hoff DD, Soares N, Gormley P, Poplack DG (1980) Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates. Cancer Treat Rep 64 : 734
30. Woodman RJ (1974) Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151). Cancer Chemother Rep 4 : 45
31. Woodman RJ, Cysyk RL, Kline I, Gang M, Venditti JM (1975) Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother Rep 59 : 689